Occam Places Jim Burns as CEO of Ensoma
Occam Global is excited to announce the placement of Jim Burns as CEO of Ensoma in May 2024. Ensoma, a 5AM and F-Prime investment, is a genomic medicines company advancing the future of medicine through precision one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system.
Prior to joining Ensoma, Jim Burns was CEO of Locanabio, a company focused on developing genetic medicines for neuromuscular and neurodegenerative diseases. Before that, he was CEO of Casebia Therapeutics, which is now part of CRISPR Therapeutics. Burns spent the bulk of his career at Genzyme and Sanofi, where he held several leadership roles with increasing responsibility, including North America site head for R&D, where he coordinated R&D operations across key therapeutic areas.
Jim earned a Bachelor of Science degree in biology from Purdue University and a Master of Science and doctoral degree in bioengineering from the University of Illinois-Chicago. His thesis work focused on drug delivery. He was a postdoctoral researcher at the University of Florida after his graduate studies.
About Ensoma’s Cutting Edge Gene Editing Technology
The name "Ensoma" is inspired by the Greek phrase "en soma," meaning "in the body." This is a perfect reflection of Ensoma's revolutionary The Engenious Platform™, which harnesses the power of a patient's own cells to cure diseases. Unlike traditional cell therapies that occur ex vivo, Ensoma's innovative technology employs Virus-like particles (VLPs) that lack viral genes, thereby minimizing immune responses often triggered by conventional viral delivery methods like AAV. This approach also offers unparalleled durability and efficacy.
By focusing on in vivo gene editing, Ensoma is setting a new standard for cell programming and control. The combination of advanced delivery mechanisms and a versatile range of DNA tools lays the groundwork for the future of in vivo genetic medicine. Specifically, in vivo editing of the immune system holds the promise of reprogramming the body's natural defenses to counteract cancer's immunosuppressive tactics. The Engenious Platform™ introduces a novel approach to cancer treatment, utilizing multi-functional engineered cell therapies derived directly from the patient. This could enable multiple engineered cell types to simultaneously express recombinant receptors, directing a powerful immune response against tumors and transform cancer care.
Occam Global's Chief Executive Officer Recruiting Services
Occam Global has a reputation for recruiting distinguished leadership in the life sciences. They have recruited Chief Executive Officers for numerous new and established biotech organizations, including Protego Biopharma, ARTBIO, Shinobi Therapeutics, Epic Bio, ChromaCode, AviadoBio, and Semma Therapeutics. Contact Occam Global today for your CEO executive recruiting needs.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.